(Press-News.org) By reprogramming a 7-year-old girl's own immune cells to attack an aggressive form of childhood leukemia, a pediatric oncologist has achieved a complete response in his patient, who faced grim prospects when she relapsed after conventional treatment. The innovative experimental therapy used bioengineered T cells, custom-designed to multiply rapidly in the patient, and then destroy leukemia cells. After the treatment, the child's doctors found that she had no evidence of cancer.
Pediatric oncologist Stephan A. Grupp, M.D., Ph.D., of The Children's Hospital of Philadelphia, and colleagues from the University of Pennsylvania presented updated results of the clinical trial involving these engineered cells at the American Society of Hematology (ASH) annual meeting today in Atlanta. Grupp is the director of Translational Research for the Center for Childhood Cancer Research at The Children's Hospital of Philadelphia, and a professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania.
Grupp's research builds on his ongoing collaboration with Penn scientists who originally developed the modified T cells as a treatment for B-cell leukemias. The Penn team reported on early results of a trial using this cell therapy in adult chronic lymphocytic leukemia (CLL) patients in August of 2011. Carl H. June, M.D., of the Perelman School of Medicine at the University of Pennsylvania, leads this research group, which along with Grupp's work, is presenting new data at the ASH meeting showing that nine of 12 patients with advanced leukemias in the clinical trial, including two children, responded to treatment with CTL019 cells.
One of the nine responding patients is the 7-year-old with acute lymphoblastic leukemia (ALL). Grupp and Penn colleagues adapted the treatment to combat ALL, the most common childhood leukemia, and also the most common childhood cancer. Although physicians can cure roughly 85 percent of ALL cases, the remaining 15 percent of such cases stubbornly resist treatment.
The CTL019 therapy, formerly called CART19, represents a new approach in cancer treatment. T cells are the workhorses of the immune system, recognizing and attacking invading disease cells. However, cancer cells fly under the radar of immune surveillance, evading detection by T cells. CAR T cells (chimeric antigen receptor T cells) are engineered to specifically target B cells, which become cancerous in certain leukemias, such as ALL and CLL, as well as types of lymphoma, another cancer of the immune cells.
CD19 is a protein found only on the surface of B cells. By creating an antibody that recognizes CD19, and physically connecting that antibody to T cells, the researchers have created a guided missile that locks in on and kills B cells, thereby attacking B-cell leukemia.
In using the CTL019 treatment in his pediatric patient, Grupp found that the very activity that destroyed leukemia cells also stimulated a highly activated immune response called a cytokine release syndrome. The child became very ill and had to be admitted to the intensive care unit.
Grupp and his team decided to counteract these toxic side effects by using 2 immunomodulating drugs that blunted the overactive immune response and rapidly relieved the child's treatment-related symptoms. These results were effective enough that this approach is now being successfully incorporated into CTL019 treatments for adults as well.
The immunomodulating drugs did not interfere with the CTL019 therapy's anti-leukemia benefits, which have persisted 6 months after the infusion of cell therapy. This persistence is essential, because the engineered T cells remain in the patient's body to protect against a recurrence of the cancer.
"These engineered T cells have proven to be active in B cell leukemia in adults," said Grupp. "We are excited to see that the CTL019 approach may be effective in untreatable cases of pediatric ALL as well. Our hope is that these results will lead to widely available treatments for high-risk B cell leukemia and lymphoma, and perhaps other cancers in the future."
"This type of pioneering research addresses the importance of timing when considering experimental therapies for relapsed patients," added Susan R. Rheingold, M.D., one of the leaders in the Children's Hospital program for children with relapsed leukemia. "To ensure newly relapsed patients with refractory leukemia meet criteria for options like CTL019, we must begin exploring these innovative approaches earlier than ever before. Having the conversation with families earlier provides them more treatment options to offer the best possible outcome."
###
In August 2012, Novartis acquired exclusive rights from Penn to CART-19, the therapy that was the subject of this clinical trial and which is now known as CTL019.
"CD19-Redirected Chimeric Antigen Receptor T (CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL-6 Antagonist Tocilizumab (toc)"
Abstract #2604 presented, Sun., Dec. 9, 2012, 6 p.m. ET; Hall B1-B2, Level 1, Building B
About the Cancer Center at The Children's Hospital of Philadelphia: The Children's Hospital of Philadelphia cares for more children with cancer than any other general pediatric hospital in the United States. Its large basic and clinical research programs are particularly strong in pediatric neuro-oncology, neuroblastoma, leukemia and lymphoma, and sarcomas. Of all pediatric institutions, Children's Hospital enrolls the most patients in national clinical trials, working in close collaboration with national organizations such as the Children's Oncology Group. Physicians at Children's Hospital have had pioneering roles in developing international standards for diagnosing and treating neuroblastoma, and in developing programs for survivors of childhood cancer.
Engineered immune cells produce complete response in child with an aggressive pediatric leukemia
CHOP oncologist achieves potent anticancer effect with engineered T cell therapy on first use in children
2012-12-10
ELSE PRESS RELEASES FROM THIS DATE:
Leukemia patients remain in remission more than 2 years after engineered T cell therapy
2012-12-10
ATLANTA -- Nine of twelve leukemia patients who received infusions of their own T cells after the cells had been genetically engineered to attack the patients' tumors responded to the therapy, which was pioneered by scientists in the Perelman School of Medicine at the University of Pennsylvania. Penn Medicine researchers will present the latest results of the trial today at the American Society of Hematology's Annual Meeting and Exposition.
The clinical trial participants, all of whom had advanced cancers, included 10 adult patients with chronic lymphocytic leukemia treated ...
Reduced intensity regimen prior to marrow transplant better for older leukemia patients
2012-12-10
COLUMBUS, Ohio – A new study led by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) shows that preparing older acute myeloid leukemia (AML) patients for bone marrow transplants with a reduced intensity conditioning regimen appears to be associated with higher rates of disease-free survival relative to the more typical treatments usually given to such patients. The study was presented at the 2012 American Society of Hematology (ASH) Annual Meeting in Atlanta, ...
Steroid hormone receptor prefers working alone to shut off immune system genes
2012-12-10
Researchers at Emory University School of Medicine have obtained a detailed molecular picture that shows how glucocorticoid hormones shut off key immune system genes.
The finding could help guide drug discovery efforts aimed at finding new anti-inflammatory drugs with fewer side effects.
The results are scheduled for publication Sunday, Dec. 9 by the journal Nature Structural & Molecular Biology.
Synthetic glucocorticoid hormones – for example, prednisone and dexamethasone -- are widely used to treat conditions such as allergies, asthma, autoimmune diseases and cancer. ...
Study finds association between oxygen deprivation before birth and ADHD
2012-12-10
PASADENA, Calif., December 10, 2012 – Children who had in-utero exposure to ischemic-hypoxic conditions, situations during which the brain is deprived of oxygen, were significantly more likely to develop attention deficit hyperactivity disorder later in life as compared to unexposed children, according to a Kaiser Permanente study published in the journal Pediatrics. The findings suggest that events in pregnancy may contribute to the occurrence of ADHD over and above well-known familial and genetic influences of the disorder.
The population-based study examines the association ...
Maintaining weight loss as important as losing it for older women
2012-12-10
WINSTON-SALEM, N.C. – Dec. 10, 2012 – When you're postmenopausal and overweight, losing weight is a good thing, but gaining back just a few pounds may actually be detrimental to your cardiovascular health.
New research from Wake Forest Baptist Medical Center found that gaining weight back after intentional weight loss is associated with negative long-term effects on some cardiometabolic (CM) risk factors in postmenopausal women.
In this paper, published online by the Journal of Gerontology: Medical Sciences, lead authors Daniel Beavers, Ph.D., and Kristen Beavers, Ph.D., ...
Tech opens communication doors for grandparents of grandkids with ASD
2012-12-10
For three years, University of Utah researchers have been deploying a computer-based design program called SketchUp in workshops to teach and develop life skills for youth on the autism spectrum. An earlier study showed that using the program helps kids develop their spatial and visual acuity, as well as to leverage those strengths to build positive social interactions.
In the latest analysis of experiences from the educational workshops, researchers have found that using the technology also helps open new communication doors with grandparents of the students. The shared ...
Sara Stablein Joins The Bridges at Rancho Santa Fe as Tennis Director
2012-12-10
Sara Stablein, named 2011 Southwestern Pro of the Year by the U.S. Professional Tennis Association (USPTA), has joined The Bridges at Rancho Santa Fe as its new Tennis Director.
Stablein will oversee instruction and programming at The Bridges' $5 million Tennis & Recreation Centre, a five-acre facility serving club members and their children and grandchildren.
"Sara is not only an accomplished competitor but she has proven herself as an effective and innovative club director," said The Bridges General Manager Sean McCune, who noted that Stablein spent ...
Montessori International School's Toddler Programs Teach Life Skills and Foster Love of Learning
2012-12-10
Forget about Chicago, the biggest toddlin' town around is Montessori International School's Toddler House, 2447 Fairbrook Road and the Toddler Community at 2401 E. Brown Road, both in Mesa.
Tots from 12 months to three years of age play with puzzles, don plastic coats and paint, sit in a circle and sing, learn Spanish, and interact happily with one another. A visit to either school denotes a surprisingly calm environment. While the occasional unhappy camper may surface, for the most part the school is free of the sound of whining and the smell of disinfectant that permeates ...
Stop Second Guessing yourself on your Ability to help your Child Become a Better Reader!
2012-12-10
The first bit of advice that a parent will receive from the school system if a child is struggling with reading is that the child needs a tutor. Parents have been listening to this advice for so long that they actually believe it.
Stop listening to those that say you can't be helpful and take on the 31 day reading challenge for yourself. All you need to do is read every day for 31 days with your child. If you are looking for tips each day, then there is a new book that was just released called 31 Days to Become a Better Reader: Increasing your Struggling Reader's Reading ...
Pure Hedonist Omnimedia Announces The Launch Of Lillie
2012-12-10
Today, Pure Hedonist Omnimedia President and Editorial Director Letitia Elizabeth announced the launch of Lillie, a bi-monthly hybrid fashion + food magazine for a new class of woman who cares deeply about the impact her personal style choices have on the environment. Lillie fills a void in the marketplace with substance, wit and unwavering respect for sustainable design and craftsmanship. Created for the nostalgic, modern and highly discerning woman, the magazine play's on women's desire to showcase their personal tastes without sacrificing lifestyle standards. This is ...
LAST 30 PRESS RELEASES:
Cercus electric stimulation enables cockroach with trajectory control and spatial cognition training
Day-long conference addresses difficult to diagnose lung disease
First-ever cardiogenic shock academy features simulation lab
Thirty-year mystery of dissonance in the “ringing” of black holes explained
Less intensive works best for agricultural soil
Arctic rivers project receives “national champion” designation from frontiers foundation
Computational biology paves the way for new ALS tests
Study offers new hope for babies born with opioid withdrawal syndrome
UT, Volkswagen Group of America celebrate research partnership
New Medicare program could dramatically improve affordability for cancer drugs – if patients enroll
Are ‘zombie’ skin cells harmful or helpful? The answer may be in their shapes
University of Cincinnati Cancer Center presents research at AACR 2025
Head and neck, breast, lung and survivorship studies headline Dana-Farber research at AACR Annual Meeting 2025
AACR: Researchers share promising results from MD Anderson clinical trials
New research explains why our waistlines expand in middle age
Advancements in muon detection: Taishan Antineutrino Observatory's innovative top veto tracker
Chips off the old block
Microvascular decompression combined with nerve combing for atypical trigeminal neuralgia
Cutting the complexity from digital carpentry
Lung immune cell type “quietly” controls inflammation in COVID-19
Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity
State and sociodemographic trends in US cigarette smoking with future projections
Young adults drive historic decline in smoking
NFCR congratulates Dr. Robert C. Bast, Jr. on receiving the AACR-Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research
Chimpanzee stem cells offer new insights into early embryonic development
This injected protein-like polymer helps tissues heal after a heart attack
FlexTech inaugural issue launches, pioneering interdisciplinary innovation in flexible technology
In Down syndrome mice, 40Hz light and sound improve cognition, neurogenesis, connectivity
Methyl eugenol: potential to inhibit oxidative stress, address related diseases, and its toxicological effects
A vascularized multilayer chip reveals shear stress-induced angiogenesis in diverse fluid conditions
[Press-News.org] Engineered immune cells produce complete response in child with an aggressive pediatric leukemiaCHOP oncologist achieves potent anticancer effect with engineered T cell therapy on first use in children